Journal of Medicinal Chemistry · 2004 · 97 citations · 4 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryMolecular PharmacologyEnzyme InhibitionLigand BindingLigand-based DesignMolecular DockingMolecular Targets Of DrugsPotency OptimizationEnzyme Inhibitor DiscoveryPoly Adp-ribose Polymerase InhibitorsPoly(adp-ribose) Polymerase 1Poly(adp-ribose) Polymerase ActivityPoly(adp-ribose) Polymerase InhibitionPoly(adp-ribose) Polymerase InhibitorsPoly(adp-ribose) Polymerase TargetsStructure-based Ligand Design
A novel class of quinazolinone derivatives as potent poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors has been discovered. Key to success was application of a rational discovery strategy involving structure-based design, combinatorial chemistry, and classical SAR for improvement of potency and bioavailability. The new inhibitors were shown to bind to the nicotinamide-ribose binding site (NI site) and the adenosine-ribose binding site (AD site) of NAD+.
4
Allen S. Mandir, Serge Przedborski, Vernice Jackson‐Lewis et al. · Proceedings of the National Academy of Sciences · 1999 · 381 citations